文献速递哮喘

tezepelumab对口服糖皮质激素依赖性哮喘的激素节约效果评估(SOURCE):一项随机、安慰剂对照3期研究

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
PubMed 文献 · Lancet Respir Med · 2022-03-29

SOURCE研究纳入150例口服糖皮质激素依赖性哮喘成人患者,随机接受tezepelumab 210 mg或安慰剂每4周皮下注射48周。tezepelumab耐受性良好。

要点

  • 总体人群中tezepelumab未显著改善口服激素减量主要终点。
  • 基线血嗜酸性粒细胞≥150个/μL者tezepelumab显示激素节约优势。
  • tezepelumab安全性与安慰剂相当,未发现新的安全性问题。

核心结论

  • 在口服糖皮质激素依赖性哮喘总体人群中,tezepelumab相比安慰剂未显著改善口服激素减量。
  • 在基线血嗜酸性粒细胞计数≥150个/μL的参与者中观察到tezepelumab的激素节约改善。

研究设计与样本

  • 3期、多中心、随机、双盲、安慰剂对照研究,在7个国家60个中心开展。
  • 150例18-80岁医生诊断哮喘患者随机接受tezepelumab 210 mg(n=74)或安慰剂(n=76)皮下注射每4周一次,治疗48周。
  • 治疗期包括4周诱导期、36周口服激素减量期和8周维持期。
  • 主要终点为第48周每日口服激素剂量较基线分类百分比减少且不失去哮喘控制。
  • 效力与安全性分析纳入所有至少接受一剂研究药物的参与者。

主要发现

  • tezepelumab组74例中53例(72%)报告不良事件,安慰剂组76例中65例(86%)报告不良事件。
  • 严重不良事件tezepelumab组12例(16%),安慰剂组16例(21%)。

临床怎么用

  • 对于口服糖皮质激素依赖性哮喘成人患者,tezepelumab总体未显著改善激素减量,不应普遍用于该目的。
  • 基线血嗜酸性粒细胞≥150个/μL的患者可能从tezepelumab获得激素节约获益,可考虑作为选择依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma. METHODS: We conducted this phase 3, multicentre, randomised, double-blind, placebo-controlled study across 60 sites in seven countries. Participants aged 18-80 years with physician-diagnosed asthma, who had been receiving medium-dose or high-dose inhaled corticosteroids and had at least one asthma exacerbation in the 12 months before screening were eligible. Patients who were receiving medium-dose inhaled corticosteroids must have had their dose increased to a high dose for at least 3 months before screening. After an oral corticosteroid optimisation phase of up to 8 weeks, participants were randomly assigned according to a computer-generated fixed block randomisation sequence to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks during a 48 week treatment period (4 week induction phase, 36 week oral corticosteroid reduction phase, and 8 week maintenance phase). Randomisation was stratified by region. Participants, investigators, and site staff were masked to treatment assignment. The primary endpoint was the categorised percentage reduction from baseline in daily oral corticosteroid dose at week 48 without the loss of asthma control. Efficacy and safety endpoints were assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT03406078. FINDINGS: Between March 5, 2018, and Sept 27, 2019, 150 participants were randomly assigned to receive tezepelumab 210 mg (n=74) or placebo (n=76). The cumulative odds of achieving a category of greater percentage reduction in an oral corticosteroid dose for daily maintenance at week 48 were similar with tezepelumab or placebo in the overall population (odds ratio [OR] 1·28 [95% CI 0·69-2·35], p=0·43; the primary endpoint was not met). The cumulative odds were higher with tezepelumab than with placebo in participants with baseline blood eosinophil counts of at least 150 cells per μL (2·58 [1·16-5·75]), but not in participants with counts below 150 cells per μL (0·40 [0·14-1·13]). Tezepelumab was well tolerated, with no safety concerns identified. 53 (72%) of 74 tezepelumab-assigned participants and 65 (86%) of 76 placebo-assigned participants reported an adverse event. Serious adverse events were reported in 12 (16%) participants in the tezepelumab group and 16 (21%) participants in the placebo group. INTERPRETATION: We did not observe a significant improvement in oral corticosteroid dose reduction with tezepelumab versus placebo in the overall population of this oral corticosteroid-sparing study, although an improvement was observed in participants with baseline blood eosinophil counts of at least 150 cells per μL. FUNDING: AstraZeneca and Amgen.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022. PMID: 35364018. doi:10.1016/S2213-2600(21)00537-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。